Idanuz

Icatibant, the active ingredient in Idanuz, is a bradykinin B2 receptor antagonist presented as an injectable solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency. The medication is formulated for rapid subcutaneous administration, allowing prompt symptom relief.

GNH USA supplies Idanuz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a quality‑focused supply chain that ensures product integrity and provides technical documentation for customers.

Idanuz, a bradykinin B2 receptor antagonist, is used to manage hereditary angioedema attacks.

- Acute hereditary angioedema (C1‑inhibitor deficiency): rapid reduction of swelling during attacks. - Hereditary angioedema type I: alleviates edema and improves patient comfort. - Hereditary angioedema type II: provides prompt symptom relief and shortens attack duration.

Idanuz may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: discomfort at the subcutaneous injection site. - Redness or swelling: localized erythema and edema. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - Hypotension: significant drop in blood pressure. - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe injection site necrosis: tissue damage at the injection area.

When prescribing Idanuz, consider the following precautions to ensure safe use.

- Pregnancy: consult a healthcare professional before use. - Breastfeeding: evaluate potential risks to the infant. - Renal impairment: monitor patients with reduced kidney function. - Concomitant ACE inhibitor therapy: use caution due to possible additive bradykinin effects. - Known hypersensitivity: avoid administration in patients with previous allergic reactions to icatibant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idanuz can interact with other medicines; awareness of these interactions helps manage patient therapy.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels, heightening risk of angioedema. - Other bradykinin B2 receptor antagonists: concurrent use can lead to excessive blockade.

Moderate Interactions (Monitor Closely): - NSAIDs: may augment risk of swelling or gastrointestinal irritation. - Estrogen‑containing contraceptives: can exacerbate hereditary angioedema symptoms. - Diuretics: monitor blood pressure and electrolyte balance during therapy.